The change will expand access to the diabetes and weight-loss drugs. But it will also complicate the future of compounded ...
Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...
The FDA has removed two of Eli Lilly's in-demand weight-loss and diabetes drugs from its shortage list. Diabetes drug ...
As digital healthcare grows, obtaining medications like Zepbound through online prescriptions has become increasingly popular ...
The US Food and Drug Administration (FDA) has declared an end to the shortage of tirzepatide, the active ingredient in Eli ...
After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has been ...
Tirzepatide injection (Zepbound, Mounjaro) is officially off the FDA's drug shortage list, meaning compounders can no longer prepare and dispense the drug.